Following a strong reporting period, BioTie's North American partner Somaxon Pharmaceuticals has announced encouraging results from a pilot Phase 2 clinical trial for smoking cessation using nalmefene. The positive outcome is anticipated to bolster confidence in the potential of this treatment, signaling promising prospects for future developments in the field.